#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The World Health Organization ( WHO ) classifies gliomas into four categories based on malignancy and overall survival ( OS ) .
2-1	16-19	The	organization[2]	new[2]	appos	2-6[0_2]
2-2	20-25	World	organization[2]	new[2]	_	_
2-3	26-32	Health	organization[2]	new[2]	_	_
2-4	33-45	Organization	organization[2]	new[2]	_	_
2-5	46-47	(	_	_	_	_
2-6	48-51	WHO	organization	giv	_	_
2-7	52-53	)	_	_	_	_
2-8	54-64	classifies	_	_	_	_
2-9	65-72	gliomas	abstract	new	_	_
2-10	73-77	into	_	_	_	_
2-11	78-82	four	abstract[5]	new[5]	_	_
2-12	83-93	categories	abstract[5]	new[5]	_	_
2-13	94-99	based	abstract[5]	new[5]	_	_
2-14	100-102	on	abstract[5]	new[5]	_	_
2-15	103-113	malignancy	abstract[5]|abstract	new[5]|new	coref	15-12[126_0]
2-16	114-117	and	abstract[5]	new[5]	_	_
2-17	118-125	overall	abstract[5]|event[7]	new[5]|new[7]	coref	4-14[0_7]
2-18	126-134	survival	abstract[5]|event[7]	new[5]|new[7]	_	_
2-19	135-136	(	_	_	_	_
2-20	137-139	OS	abstract	new	coref	4-1[14_0]
2-21	140-141	)	_	_	_	_
2-22	142-143	.	_	_	_	_

#Text=Glioblastoma is the most malignant form of astrocytoma that is fast-growing ( grade 4 glioma ) .
3-1	144-156	Glioblastoma	abstract	new	coref	3-3[10_0]
3-2	157-159	is	_	_	_	_
3-3	160-163	the	abstract[10]	giv[10]	coref	4-5[0_10]
3-4	164-168	most	abstract[10]	giv[10]	_	_
3-5	169-178	malignant	abstract[10]	giv[10]	_	_
3-6	179-183	form	abstract[10]	giv[10]	_	_
3-7	184-186	of	abstract[10]	giv[10]	_	_
3-8	187-198	astrocytoma	abstract[10]|abstract	giv[10]|new	_	_
3-9	199-203	that	abstract[10]	giv[10]	_	_
3-10	204-206	is	abstract[10]	giv[10]	_	_
3-11	207-219	fast-growing	abstract[10]	giv[10]	_	_
3-12	220-221	(	_	_	_	_
3-13	222-227	grade	abstract[12]|abstract[13]	new[12]|new[13]	coref	8-1[0_13]
3-14	228-229	4	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-15	230-236	glioma	abstract[13]	new[13]	_	_
3-16	237-238	)	_	_	_	_
3-17	239-240	.	_	_	_	_

#Text=The median OS of glioblastoma is 9 – 15 months and the five-year survival rate remains less than 5 % .
4-1	241-244	The	abstract[14]	giv[14]	coref	4-7[16_14]
4-2	245-251	median	abstract[14]	giv[14]	_	_
4-3	252-254	OS	abstract[14]	giv[14]	_	_
4-4	255-257	of	abstract[14]	giv[14]	_	_
4-5	258-270	glioblastoma	abstract[14]|abstract	giv[14]|giv	coref	5-25
4-6	271-273	is	_	_	_	_
4-7	274-275	9	abstract[16]	giv[16]	coref	21-20[196_16]
4-8	276-277	–	abstract[16]	giv[16]	_	_
4-9	278-280	15	abstract[16]	giv[16]	_	_
4-10	281-287	months	abstract[16]	giv[16]	_	_
4-11	288-291	and	_	_	_	_
4-12	292-295	the	abstract[18]	new[18]	_	_
4-13	296-305	five-year	abstract[18]	new[18]	_	_
4-14	306-314	survival	event|abstract[18]	giv|new[18]	coref	22-6
4-15	315-319	rate	abstract[18]	new[18]	_	_
4-16	320-327	remains	_	_	_	_
4-17	328-332	less	abstract[19]	new[19]	_	_
4-18	333-337	than	abstract[19]	new[19]	_	_
4-19	338-339	5	abstract[19]	new[19]	_	_
4-20	340-341	%	abstract[19]	new[19]	_	_
4-21	342-343	.	_	_	_	_

#Text=Radiotherapy with six cycles of concomitant temozolomide , an oral alkylating agent with minimal additional toxicity , is the standard treatment after surgery in glioblastoma patients .
5-1	344-356	Radiotherapy	abstract[20]	new[20]	coref	5-19[25_20]
5-2	357-361	with	abstract[20]	new[20]	_	_
5-3	362-365	six	abstract[20]|event[21]	new[20]|new[21]	_	_
5-4	366-372	cycles	abstract[20]|event[21]	new[20]|new[21]	_	_
5-5	373-375	of	abstract[20]|event[21]	new[20]|new[21]	_	_
5-6	376-387	concomitant	abstract[20]|event[21]|substance[22]	new[20]|new[21]|new[22]	appos	5-9[23_22]
5-7	388-400	temozolomide	abstract[20]|event[21]|substance[22]	new[20]|new[21]|new[22]	_	_
5-8	401-402	,	_	_	_	_
5-9	403-405	an	substance[23]	giv[23]	coref	16-3[0_23]
5-10	406-410	oral	substance[23]	giv[23]	_	_
5-11	411-421	alkylating	substance[23]	giv[23]	_	_
5-12	422-427	agent	substance[23]	giv[23]	_	_
5-13	428-432	with	substance[23]	giv[23]	_	_
5-14	433-440	minimal	substance[23]|abstract[24]	giv[23]|new[24]	_	_
5-15	441-451	additional	substance[23]|abstract[24]	giv[23]|new[24]	_	_
5-16	452-460	toxicity	substance[23]|abstract[24]	giv[23]|new[24]	_	_
5-17	461-462	,	_	_	_	_
5-18	463-465	is	_	_	_	_
5-19	466-469	the	abstract[25]	giv[25]	_	_
5-20	470-478	standard	abstract[25]	giv[25]	_	_
5-21	479-488	treatment	abstract[25]	giv[25]	_	_
5-22	489-494	after	abstract[25]	giv[25]	_	_
5-23	495-502	surgery	abstract[25]|event	giv[25]|new	_	_
5-24	503-505	in	abstract[25]	giv[25]	_	_
5-25	506-518	glioblastoma	abstract[25]|abstract|person[28]	giv[25]|giv|new[28]	coref|coref	6-21|21-22[197_28]
5-26	519-527	patients	abstract[25]|person[28]	giv[25]|new[28]	_	_
5-27	528-529	.	_	_	_	_

#Text=Thus , there is an immediate requirement for the early diagnosis and precise prediction of the prognosis for treatments of glioblastoma .
6-1	530-534	Thus	_	_	_	_
6-2	535-536	,	_	_	_	_
6-3	537-542	there	_	_	_	_
6-4	543-545	is	_	_	_	_
6-5	546-548	an	abstract[29]	new[29]	_	_
6-6	549-558	immediate	abstract[29]	new[29]	_	_
6-7	559-570	requirement	abstract[29]	new[29]	_	_
6-8	571-574	for	abstract[29]	new[29]	_	_
6-9	575-578	the	abstract[29]|event[30]	new[29]|new[30]	_	_
6-10	579-584	early	abstract[29]|event[30]	new[29]|new[30]	_	_
6-11	585-594	diagnosis	abstract[29]|event[30]	new[29]|new[30]	_	_
6-12	595-598	and	abstract[29]	new[29]	_	_
6-13	599-606	precise	abstract[29]|event[31]	new[29]|new[31]	coref	22-13[205_31]
6-14	607-617	prediction	abstract[29]|event[31]	new[29]|new[31]	_	_
6-15	618-620	of	abstract[29]|event[31]	new[29]|new[31]	_	_
6-16	621-624	the	abstract[29]|event[31]|abstract[32]	new[29]|new[31]|new[32]	coref	22-13[0_32]
6-17	625-634	prognosis	abstract[29]|event[31]|abstract[32]	new[29]|new[31]|new[32]	_	_
6-18	635-638	for	abstract[29]|event[31]|abstract[32]	new[29]|new[31]|new[32]	_	_
6-19	639-649	treatments	abstract[29]|event[31]|abstract[32]|abstract[33]	new[29]|new[31]|new[32]|new[33]	_	_
6-20	650-652	of	abstract[29]|event[31]|abstract[32]|abstract[33]	new[29]|new[31]|new[32]|new[33]	_	_
6-21	653-665	glioblastoma	abstract[29]|event[31]|abstract[32]|abstract[33]|abstract	new[29]|new[31]|new[32]|new[33]|giv	coref	7-4
6-22	666-667	.	_	_	_	_

#Text=The invasiveness of glioblastoma depends on its high infiltration potential to invade the basement membranes of surrounding tissues .
7-1	668-671	The	abstract[35]	new[35]	_	_
7-2	672-684	invasiveness	abstract[35]	new[35]	_	_
7-3	685-687	of	abstract[35]	new[35]	_	_
7-4	688-700	glioblastoma	abstract[35]|abstract	new[35]|giv	ana	7-7
7-5	701-708	depends	_	_	_	_
7-6	709-711	on	_	_	_	_
7-7	712-715	its	abstract|abstract[39]	giv|new[39]	coref	20-10
7-8	716-720	high	abstract[39]	new[39]	_	_
7-9	721-733	infiltration	abstract|abstract[39]	new|new[39]	_	_
7-10	734-743	potential	abstract[39]	new[39]	_	_
7-11	744-746	to	abstract[39]	new[39]	_	_
7-12	747-753	invade	abstract[39]	new[39]	_	_
7-13	754-757	the	abstract[39]|place[41]	new[39]|new[41]	coref	10-23[67_41]
7-14	758-766	basement	abstract[39]|place|place[41]	new[39]|new|new[41]	coref	10-24
7-15	767-776	membranes	abstract[39]|place[41]	new[39]|new[41]	_	_
7-16	777-779	of	abstract[39]|place[41]	new[39]|new[41]	_	_
7-17	780-791	surrounding	abstract[39]|place[41]|object[42]	new[39]|new[41]|new[42]	coref	17-29[156_42]
7-18	792-799	tissues	abstract[39]|place[41]|object[42]	new[39]|new[41]|new[42]	_	_
7-19	800-801	.	_	_	_	_

#Text=Glioma cells are reprogrammed to have increased motility via weakened cell adhesions and a dysregulated cytoskeleton ; this is known as epithelial – mesenchymal transition ( EMT ) .
8-1	802-808	Glioma	abstract|plant[44]	giv|new[44]	coref	12-25
8-2	809-814	cells	plant[44]	new[44]	_	_
8-3	815-818	are	_	_	_	_
8-4	819-831	reprogrammed	_	_	_	_
8-5	832-834	to	_	_	_	_
8-6	835-839	have	_	_	_	_
8-7	840-849	increased	abstract[45]	new[45]	ana	8-18[0_45]
8-8	850-858	motility	abstract[45]	new[45]	_	_
8-9	859-862	via	_	_	_	_
8-10	863-871	weakened	abstract[47]	new[47]	_	_
8-11	872-876	cell	place|abstract[47]	new|new[47]	coref	9-9
8-12	877-886	adhesions	abstract[47]	new[47]	_	_
8-13	887-890	and	_	_	_	_
8-14	891-892	a	person[48]	new[48]	_	_
8-15	893-905	dysregulated	person[48]	new[48]	_	_
8-16	906-918	cytoskeleton	person[48]	new[48]	_	_
8-17	919-920	;	_	_	_	_
8-18	921-925	this	abstract	giv	_	_
8-19	926-928	is	_	_	_	_
8-20	929-934	known	_	_	_	_
8-21	935-937	as	_	_	_	_
8-22	938-948	epithelial	event[50]	new[50]	_	_
8-23	949-950	–	event[50]	new[50]	_	_
8-24	951-962	mesenchymal	event[50]	new[50]	_	_
8-25	963-973	transition	event[50]	new[50]	_	_
8-26	974-975	(	_	_	_	_
8-27	976-979	EMT	abstract	new	coref	9-1
8-28	980-981	)	_	_	_	_
8-29	982-983	.	_	_	_	_

#Text=EMT is a biological process that polarized epithelial cell sheets undergo , wherein multiple biochemical changes culminate in mesenchymal phenotypes .
9-1	984-987	EMT	abstract	giv	coref	9-3[53_0]
9-2	988-990	is	_	_	_	_
9-3	991-992	a	abstract[53]	giv[53]	coref	11-1[0_53]
9-4	993-1003	biological	abstract[53]	giv[53]	_	_
9-5	1004-1011	process	abstract[53]	giv[53]	_	_
9-6	1012-1016	that	abstract[53]	giv[53]	_	_
9-7	1017-1026	polarized	abstract[53]|object[55]	giv[53]|new[55]	_	_
9-8	1027-1037	epithelial	abstract[53]|object[55]	giv[53]|new[55]	_	_
9-9	1038-1042	cell	abstract[53]|place|object[55]	giv[53]|giv|new[55]	coref	10-17
9-10	1043-1049	sheets	abstract[53]|object[55]	giv[53]|new[55]	_	_
9-11	1050-1057	undergo	abstract[53]	giv[53]	_	_
9-12	1058-1059	,	_	_	_	_
9-13	1060-1067	wherein	_	_	_	_
9-14	1068-1076	multiple	abstract[56]	new[56]	coref	18-3[162_56]
9-15	1077-1088	biochemical	abstract[56]	new[56]	_	_
9-16	1089-1096	changes	abstract[56]	new[56]	_	_
9-17	1097-1106	culminate	_	_	_	_
9-18	1107-1109	in	_	_	_	_
9-19	1110-1121	mesenchymal	abstract[57]	new[57]	coref	12-6[0_57]
9-20	1122-1132	phenotypes	abstract[57]	new[57]	_	_
9-21	1133-1134	.	_	_	_	_

#Text=Cells display altered morphology , resistance to chemotherapy , and anoikis ( a form of programmed cell death of cells detached from the basement membranes ) .
10-1	1135-1140	Cells	object	new	coref	10-20[65_0]
10-2	1141-1148	display	_	_	_	_
10-3	1149-1156	altered	abstract[59]	new[59]	_	_
10-4	1157-1167	morphology	abstract[59]	new[59]	_	_
10-5	1168-1169	,	_	_	_	_
10-6	1170-1180	resistance	abstract[60]	new[60]	_	_
10-7	1181-1183	to	abstract[60]	new[60]	_	_
10-8	1184-1196	chemotherapy	abstract[60]|event	new[60]|new	_	_
10-9	1197-1198	,	_	_	_	_
10-10	1199-1202	and	_	_	_	_
10-11	1203-1210	anoikis	abstract	new	_	_
10-12	1211-1212	(	_	_	_	_
10-13	1213-1214	a	event[64]	new[64]	_	_
10-14	1215-1219	form	event[64]	new[64]	_	_
10-15	1220-1222	of	event[64]	new[64]	_	_
10-16	1223-1233	programmed	event[64]	new[64]	_	_
10-17	1234-1238	cell	place|event[64]	giv|new[64]	coref	16-27
10-18	1239-1244	death	event[64]	new[64]	_	_
10-19	1245-1247	of	event[64]	new[64]	_	_
10-20	1248-1253	cells	event[64]|object[65]	new[64]|giv[65]	coref	12-25[90_65]
10-21	1254-1262	detached	event[64]|object[65]	new[64]|giv[65]	_	_
10-22	1263-1267	from	event[64]|object[65]	new[64]|giv[65]	_	_
10-23	1268-1271	the	event[64]|object[65]|place[67]	new[64]|giv[65]|giv[67]	_	_
10-24	1272-1280	basement	event[64]|object[65]|place|place[67]	new[64]|giv[65]|giv|giv[67]	_	_
10-25	1281-1290	membranes	event[64]|object[65]|place[67]	new[64]|giv[65]|giv[67]	_	_
10-26	1291-1292	)	_	_	_	_
10-27	1293-1294	.	_	_	_	_

#Text=EMT is also involved in other biological processes , including implantation and embryo development , wound healing , tissue regeneration , and neoplasia associated with cancer progression .
11-1	1295-1298	EMT	abstract	giv	coref	12-10
11-2	1299-1301	is	_	_	_	_
11-3	1302-1306	also	_	_	_	_
11-4	1307-1315	involved	_	_	_	_
11-5	1316-1318	in	_	_	_	_
11-6	1319-1324	other	abstract[69]	new[69]	_	_
11-7	1325-1335	biological	abstract[69]	new[69]	_	_
11-8	1336-1345	processes	abstract[69]	new[69]	_	_
11-9	1346-1347	,	abstract[69]	new[69]	_	_
11-10	1348-1357	including	abstract[69]	new[69]	_	_
11-11	1358-1370	implantation	abstract[69]|event	new[69]|new	_	_
11-12	1371-1374	and	abstract[69]	new[69]	_	_
11-13	1375-1381	embryo	abstract[69]|substance|event[72]	new[69]|new|new[72]	_	_
11-14	1382-1393	development	abstract[69]|event[72]	new[69]|new[72]	_	_
11-15	1394-1395	,	abstract[69]	new[69]	_	_
11-16	1396-1401	wound	abstract[69]|abstract|event[74]	new[69]|new|new[74]	_	_
11-17	1402-1409	healing	abstract[69]|event[74]	new[69]|new[74]	_	_
11-18	1410-1411	,	abstract[69]	new[69]	_	_
11-19	1412-1418	tissue	abstract[69]|object|event[76]	new[69]|new|new[76]	_	_
11-20	1419-1431	regeneration	abstract[69]|event[76]	new[69]|new[76]	_	_
11-21	1432-1433	,	abstract[69]	new[69]	_	_
11-22	1434-1437	and	abstract[69]	new[69]	_	_
11-23	1438-1447	neoplasia	abstract[69]|abstract[77]	new[69]|new[77]	_	_
11-24	1448-1458	associated	abstract[69]|abstract[77]	new[69]|new[77]	_	_
11-25	1459-1463	with	abstract[69]|abstract[77]	new[69]|new[77]	_	_
11-26	1464-1470	cancer	abstract[69]|abstract[77]|abstract|event[79]	new[69]|new[77]|new|new[79]	coref|coref	12-4|19-1[173_79]
11-27	1471-1482	progression	abstract[69]|abstract[77]|event[79]	new[69]|new[77]|new[79]	_	_
11-28	1483-1484	.	_	_	_	_

#Text=During invasion in cancer , phenotypes also change as EMT is mainly induced by hypoxia and the transforming growth factor ( TGF)-β released from glioma stem cells ( GSCs ) , mesenchymal stem cells ( MSCs ) , and myeloid cells recruited by hypoxia .
12-1	1485-1491	During	_	_	_	_
12-2	1492-1500	invasion	event[80]	new[80]	_	_
12-3	1501-1503	in	event[80]	new[80]	_	_
12-4	1504-1510	cancer	event[80]|abstract	new[80]|giv	coref	14-5
12-5	1511-1512	,	_	_	_	_
12-6	1513-1523	phenotypes	abstract	giv	_	_
12-7	1524-1528	also	_	_	_	_
12-8	1529-1535	change	_	_	_	_
12-9	1536-1538	as	_	_	_	_
12-10	1539-1542	EMT	abstract	giv	coref	20-6
12-11	1543-1545	is	_	_	_	_
12-12	1546-1552	mainly	_	_	_	_
12-13	1553-1560	induced	_	_	_	_
12-14	1561-1563	by	_	_	_	_
12-15	1564-1571	hypoxia	abstract	new	coref	12-44
12-16	1572-1575	and	_	_	_	_
12-17	1576-1579	the	abstract[86]	new[86]	appos	12-22[0_86]
12-18	1580-1592	transforming	abstract[85]|abstract[86]	new[85]|new[86]	_	_
12-19	1593-1599	growth	abstract[85]|abstract[86]	new[85]|new[86]	_	_
12-20	1600-1606	factor	abstract[86]	new[86]	_	_
12-21	1607-1608	(	_	_	_	_
12-22	1609-1615	TGF)-β	abstract	giv	_	_
12-23	1616-1624	released	_	_	_	_
12-24	1625-1629	from	_	_	_	_
12-25	1630-1636	glioma	abstract|object[90]	giv|giv[90]	coref|coref	12-32[93_90]|16-21
12-26	1637-1641	stem	plant|object[90]	new|giv[90]	coref	14-1
12-27	1642-1647	cells	object[90]	giv[90]	_	_
12-28	1648-1649	(	_	_	_	_
12-29	1650-1654	GSCs	abstract	new	coref	16-37
12-30	1655-1656	)	_	_	_	_
12-31	1657-1658	,	_	_	_	_
12-32	1659-1670	mesenchymal	person|object[93]	new|giv[93]	coref	12-40[96_93]
12-33	1671-1675	stem	object[93]	giv[93]	_	_
12-34	1676-1681	cells	object[93]	giv[93]	_	_
12-35	1682-1683	(	_	_	_	_
12-36	1684-1688	MSCs	abstract	new	_	_
12-37	1689-1690	)	_	_	_	_
12-38	1691-1692	,	_	_	_	_
12-39	1693-1696	and	_	_	_	_
12-40	1697-1704	myeloid	object|object[96]	new|giv[96]	coref	14-1[103_96]
12-41	1705-1710	cells	object[96]	giv[96]	_	_
12-42	1711-1720	recruited	object[96]	giv[96]	_	_
12-43	1721-1723	by	object[96]	giv[96]	_	_
12-44	1724-1731	hypoxia	object[96]|abstract	giv[96]|giv	_	_
12-45	1732-1733	.	_	_	_	_

#Text=The reverse is also essential for the formation of distant or disseminated tumor nodules .
13-1	1734-1737	The	event[98]	new[98]	_	_
13-2	1738-1745	reverse	event[98]	new[98]	_	_
13-3	1746-1748	is	_	_	_	_
13-4	1749-1753	also	_	_	_	_
13-5	1754-1763	essential	_	_	_	_
13-6	1764-1767	for	_	_	_	_
13-7	1768-1771	the	event[99]	new[99]	_	_
13-8	1772-1781	formation	event[99]	new[99]	_	_
13-9	1782-1784	of	event[99]	new[99]	_	_
13-10	1785-1792	distant	event[99]|abstract[101]	new[99]|new[101]	_	_
13-11	1793-1795	or	event[99]|abstract[101]	new[99]|new[101]	_	_
13-12	1796-1808	disseminated	event[99]|abstract[101]	new[99]|new[101]	_	_
13-13	1809-1814	tumor	event[99]|abstract|abstract[101]	new[99]|new|new[101]	coref	19-1
13-14	1815-1822	nodules	event[99]|abstract[101]	new[99]|new[101]	_	_
13-15	1823-1824	.	_	_	_	_

#Text=Stem cells , including cancer stem cells ( CSCs ) , are pluripotent and capable of self-renewal , like induced pluripotent stem ( iPS ) cells induced by the transcription factors Oct3/4 , Sox2 , c-Myc , and Klf4 or OCT4 , SOX2 , NANOG , and LIN28 .
14-1	1825-1829	Stem	plant|object[103]	giv|giv[103]	coref|coref	14-6|14-5[106_103]
14-2	1830-1835	cells	object[103]	giv[103]	_	_
14-3	1836-1837	,	object[103]	giv[103]	_	_
14-4	1838-1847	including	object[103]	giv[103]	_	_
14-5	1848-1854	cancer	object[103]|abstract|object[106]	giv[103]|giv|giv[106]	coref	14-20[111_106]
14-6	1855-1859	stem	object[103]|plant|object[106]	giv[103]|giv|giv[106]	coref	14-20[109_0]
14-7	1860-1865	cells	object[103]|object[106]	giv[103]|giv[106]	_	_
14-8	1866-1867	(	_	_	_	_
14-9	1868-1872	CSCs	organization	new	_	_
14-10	1873-1874	)	_	_	_	_
14-11	1875-1876	,	_	_	_	_
14-12	1877-1880	are	_	_	_	_
14-13	1881-1892	pluripotent	_	_	_	_
14-14	1893-1896	and	_	_	_	_
14-15	1897-1904	capable	_	_	_	_
14-16	1905-1907	of	_	_	_	_
14-17	1908-1920	self-renewal	abstract	new	_	_
14-18	1921-1922	,	_	_	_	_
14-19	1923-1927	like	_	_	_	_
14-20	1928-1935	induced	plant[109]|object[111]	giv[109]|giv[111]	coref	16-21[140_111]
14-21	1936-1947	pluripotent	plant[109]|object[111]	giv[109]|giv[111]	_	_
14-22	1948-1952	stem	plant[109]|object[111]	giv[109]|giv[111]	_	_
14-23	1953-1954	(	object[111]	giv[111]	_	_
14-24	1955-1958	iPS	abstract|object[111]	new|giv[111]	_	_
14-25	1959-1960	)	object[111]	giv[111]	_	_
14-26	1961-1966	cells	object[111]	giv[111]	_	_
14-27	1967-1974	induced	object[111]	giv[111]	_	_
14-28	1975-1977	by	object[111]	giv[111]	_	_
14-29	1978-1981	the	object[111]|abstract[113]|abstract[114]	giv[111]|new[113]|new[114]	coref	16-26[142_113]
14-30	1982-1995	transcription	object[111]|abstract|abstract[113]|abstract[114]	giv[111]|new|new[113]|new[114]	_	_
14-31	1996-2003	factors	object[111]|abstract[113]|abstract[114]	giv[111]|new[113]|new[114]	_	_
14-32	2004-2010	Oct3/4	object[111]|abstract[114]	giv[111]|new[114]	_	_
14-33	2011-2012	,	object[111]	giv[111]	_	_
14-34	2013-2017	Sox2	object[111]|abstract	giv[111]|new	_	_
14-35	2018-2019	,	object[111]	giv[111]	_	_
14-36	2020-2025	c-Myc	object[111]|abstract	giv[111]|new	_	_
14-37	2026-2027	,	object[111]	giv[111]	_	_
14-38	2028-2031	and	object[111]	giv[111]	_	_
14-39	2032-2036	Klf4	object[111]|substance	giv[111]|new	_	_
14-40	2037-2039	or	object[111]	giv[111]	_	_
14-41	2040-2044	OCT4	object[111]|abstract	giv[111]|new	coref	15-4
14-42	2045-2046	,	object[111]	giv[111]	_	_
14-43	2047-2051	SOX2	object[111]|abstract	giv[111]|new	_	_
14-44	2052-2053	,	object[111]	giv[111]	_	_
14-45	2054-2059	NANOG	object[111]|abstract	giv[111]|new	coref	16-17
14-46	2060-2061	,	object[111]	giv[111]	_	_
14-47	2062-2065	and	object[111]	giv[111]	_	_
14-48	2066-2071	LIN28	object[111]|abstract	giv[111]|new	_	_
14-49	2072-2073	.	_	_	_	_

#Text=The expression of OCT4 , MYC , and KLF4 increases with increasing malignancy in astrocytomas , whereas MYC expression slightly decreases in recurrent glioblastomas .
15-1	2074-2077	The	abstract[122]	new[122]	coref	15-18[129_122]
15-2	2078-2088	expression	abstract[122]	new[122]	_	_
15-3	2089-2091	of	abstract[122]	new[122]	_	_
15-4	2092-2096	OCT4	abstract[122]|abstract	new[122]|giv	coref	16-19
15-5	2097-2098	,	abstract[122]	new[122]	_	_
15-6	2099-2102	MYC	abstract[122]|abstract	new[122]|new	coref	15-18
15-7	2103-2104	,	abstract[122]	new[122]	_	_
15-8	2105-2108	and	abstract[122]	new[122]	_	_
15-9	2109-2113	KLF4	abstract[122]|abstract	new[122]|new	coref	16-11
15-10	2114-2123	increases	_	_	_	_
15-11	2124-2128	with	_	_	_	_
15-12	2129-2139	increasing	abstract[126]	giv[126]	_	_
15-13	2140-2150	malignancy	abstract[126]	giv[126]	_	_
15-14	2151-2153	in	_	_	_	_
15-15	2154-2166	astrocytomas	abstract	new	_	_
15-16	2167-2168	,	_	_	_	_
15-17	2169-2176	whereas	_	_	_	_
15-18	2177-2180	MYC	abstract|abstract[129]	giv|giv[129]	_	_
15-19	2181-2191	expression	abstract[129]	giv[129]	_	_
15-20	2192-2200	slightly	_	_	_	_
15-21	2201-2210	decreases	_	_	_	_
15-22	2211-2213	in	_	_	_	_
15-23	2214-2223	recurrent	animal[130]	new[130]	_	_
15-24	2224-2237	glioblastomas	animal[130]	new[130]	_	_
15-25	2238-2239	.	_	_	_	_

#Text=Exposure to temozolomide ( TMZ ) increases the expression of KLF4 and reduces the expression of Nanog and OCT4 in glioma cells , indicating that stem cell factors , especially KLF4 , play pivotal roles in GSCs .
16-1	2240-2248	Exposure	abstract[131]	new[131]	_	_
16-2	2249-2251	to	abstract[131]	new[131]	_	_
16-3	2252-2264	temozolomide	abstract[131]|substance	new[131]|giv	_	_
16-4	2265-2266	(	_	_	_	_
16-5	2267-2270	TMZ	abstract	new	_	_
16-6	2271-2272	)	_	_	_	_
16-7	2273-2282	increases	_	_	_	_
16-8	2283-2286	the	abstract[134]	new[134]	_	_
16-9	2287-2297	expression	abstract[134]	new[134]	_	_
16-10	2298-2300	of	abstract[134]	new[134]	_	_
16-11	2301-2305	KLF4	abstract[134]|abstract	new[134]|giv	_	_
16-12	2306-2309	and	_	_	_	_
16-13	2310-2317	reduces	_	_	_	_
16-14	2318-2321	the	abstract[136]	new[136]	coref	21-17[0_136]
16-15	2322-2332	expression	abstract[136]	new[136]	_	_
16-16	2333-2335	of	abstract[136]	new[136]	_	_
16-17	2336-2341	Nanog	abstract[136]|abstract	new[136]|giv	_	_
16-18	2342-2345	and	abstract[136]	new[136]	_	_
16-19	2346-2350	OCT4	abstract[136]|abstract	new[136]|giv	_	_
16-20	2351-2353	in	_	_	_	_
16-21	2354-2360	glioma	abstract|object[140]	giv|giv[140]	coref	17-30
16-22	2361-2366	cells	object[140]	giv[140]	_	_
16-23	2367-2368	,	_	_	_	_
16-24	2369-2379	indicating	_	_	_	_
16-25	2380-2384	that	_	_	_	_
16-26	2385-2389	stem	abstract[142]	giv[142]	appos	16-30[143_142]
16-27	2390-2394	cell	place|abstract[142]	giv|giv[142]	coref	17-23
16-28	2395-2402	factors	abstract[142]	giv[142]	_	_
16-29	2403-2404	,	_	_	_	_
16-30	2405-2415	especially	abstract[143]	giv[143]	_	_
16-31	2416-2420	KLF4	abstract[143]	giv[143]	_	_
16-32	2421-2422	,	_	_	_	_
16-33	2423-2427	play	_	_	_	_
16-34	2428-2435	pivotal	abstract[144]	new[144]	_	_
16-35	2436-2441	roles	abstract[144]	new[144]	_	_
16-36	2442-2444	in	abstract[144]	new[144]	_	_
16-37	2445-2449	GSCs	abstract[144]|abstract	new[144]|giv	coref	17-20
16-38	2450-2451	.	_	_	_	_

#Text=The most common GSC marker CD133 , also known as prominin-1 ( PROM1 ) , is used to isolate GSCs by fluorescence-activated cell sorting ( FACS ) in primary glioma tissues and the cell lines U87 and T98G .
17-1	2452-2455	The	abstract[147]|abstract[148]	new[147]|new[148]	_	_
17-2	2456-2460	most	abstract[147]|abstract[148]	new[147]|new[148]	_	_
17-3	2461-2467	common	abstract[147]|abstract[148]	new[147]|new[148]	_	_
17-4	2468-2471	GSC	abstract|abstract[147]|abstract[148]	new|new[147]|new[148]	coref	23-16
17-5	2472-2478	marker	abstract[147]|abstract[148]	new[147]|new[148]	_	_
17-6	2479-2484	CD133	abstract[148]	new[148]	_	_
17-7	2485-2486	,	abstract[148]	new[148]	_	_
17-8	2487-2491	also	abstract[148]	new[148]	_	_
17-9	2492-2497	known	abstract[148]	new[148]	_	_
17-10	2498-2500	as	abstract[148]	new[148]	_	_
17-11	2501-2511	prominin-1	abstract[148]|abstract	new[148]|new	appos	17-13
17-12	2512-2513	(	_	_	_	_
17-13	2514-2519	PROM1	abstract	giv	_	_
17-14	2520-2521	)	_	_	_	_
17-15	2522-2523	,	_	_	_	_
17-16	2524-2526	is	_	_	_	_
17-17	2527-2531	used	_	_	_	_
17-18	2532-2534	to	_	_	_	_
17-19	2535-2542	isolate	_	_	_	_
17-20	2543-2547	GSCs	abstract	giv	coref	20-8
17-21	2548-2550	by	_	_	_	_
17-22	2551-2573	fluorescence-activated	abstract[153]	new[153]	appos	17-26[0_153]
17-23	2574-2578	cell	place|abstract[153]	giv|new[153]	coref	17-34
17-24	2579-2586	sorting	abstract[153]	new[153]	_	_
17-25	2587-2588	(	_	_	_	_
17-26	2589-2593	FACS	abstract	giv	_	_
17-27	2594-2595	)	_	_	_	_
17-28	2596-2598	in	_	_	_	_
17-29	2599-2606	primary	object[156]|object[157]	giv[156]|giv[157]	coref	17-29[157_156]
17-30	2607-2613	glioma	abstract|object[156]|object[157]	giv|giv[156]|giv[157]	coref	18-7
17-31	2614-2621	tissues	object[156]|object[157]	giv[156]|giv[157]	_	_
17-32	2622-2625	and	object[157]	giv[157]	_	_
17-33	2626-2629	the	object[157]|object[159]|abstract[160]	giv[157]|new[159]|new[160]	_	_
17-34	2630-2634	cell	object[157]|place|object[159]|abstract[160]	giv[157]|giv|new[159]|new[160]	coref	19-22
17-35	2635-2640	lines	object[157]|object[159]|abstract[160]	giv[157]|new[159]|new[160]	_	_
17-36	2641-2644	U87	object[157]|abstract[160]	giv[157]|new[160]	_	_
17-37	2645-2648	and	object[157]	giv[157]	_	_
17-38	2649-2653	T98G	object[157]|abstract	giv[157]|new	_	_
17-39	2654-2655	.	_	_	_	_

#Text=There are changes in metabolism in glioma and oxidative phosphorylation , glycolysis , and glutaminolysis replace redox balance , bioenergetics , and biosynthesis , respectively .
18-1	2656-2661	There	_	_	_	_
18-2	2662-2665	are	_	_	_	_
18-3	2666-2673	changes	abstract[162]	giv[162]	_	_
18-4	2674-2676	in	abstract[162]	giv[162]	_	_
18-5	2677-2687	metabolism	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
18-6	2688-2690	in	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
18-7	2691-2697	glioma	abstract[162]|abstract[163]|abstract	giv[162]|new[163]|giv	coref	19-21
18-8	2698-2701	and	_	_	_	_
18-9	2702-2711	oxidative	person[165]	new[165]	_	_
18-10	2712-2727	phosphorylation	person[165]	new[165]	_	_
18-11	2728-2729	,	_	_	_	_
18-12	2730-2740	glycolysis	substance	new	_	_
18-13	2741-2742	,	_	_	_	_
18-14	2743-2746	and	_	_	_	_
18-15	2747-2761	glutaminolysis	substance	new	_	_
18-16	2762-2769	replace	_	_	_	_
18-17	2770-2775	redox	object|abstract[169]	new|new[169]	coref	19-18[177_169]
18-18	2776-2783	balance	abstract[169]	new[169]	_	_
18-19	2784-2785	,	_	_	_	_
18-20	2786-2799	bioenergetics	abstract	new	_	_
18-21	2800-2801	,	_	_	_	_
18-22	2802-2805	and	_	_	_	_
18-23	2806-2818	biosynthesis	abstract	new	_	_
18-24	2819-2820	,	_	_	_	_
18-25	2821-2833	respectively	_	_	_	_
18-26	2834-2835	.	_	_	_	_

#Text=Tumor progression is enhanced by inflammation , which is an emerging hallmark of cancers that depends on the balance of glioma cell proliferation , migration , and escape from the immune system .
19-1	2836-2841	Tumor	abstract|event[173]	giv|giv[173]	_	_
19-2	2842-2853	progression	event[173]	giv[173]	_	_
19-3	2854-2856	is	_	_	_	_
19-4	2857-2865	enhanced	_	_	_	_
19-5	2866-2868	by	_	_	_	_
19-6	2869-2881	inflammation	abstract[174]	new[174]	_	_
19-7	2882-2883	,	abstract[174]	new[174]	_	_
19-8	2884-2889	which	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-9	2890-2892	is	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-10	2893-2895	an	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-11	2896-2904	emerging	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-12	2905-2913	hallmark	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-13	2914-2916	of	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-14	2917-2924	cancers	abstract[174]|abstract[175]|abstract	new[174]|new[175]|new	_	_
19-15	2925-2929	that	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-16	2930-2937	depends	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-17	2938-2940	on	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-18	2941-2944	the	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-19	2945-2952	balance	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-20	2953-2955	of	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-21	2956-2962	glioma	abstract[174]|abstract[175]|abstract[177]|abstract|abstract[180]	new[174]|new[175]|giv[177]|giv|new[180]	coref	23-11
19-22	2963-2967	cell	abstract[174]|abstract[175]|abstract[177]|place|abstract[180]	new[174]|new[175]|giv[177]|giv|new[180]	_	_
19-23	2968-2981	proliferation	abstract[174]|abstract[175]|abstract[177]|abstract[180]	new[174]|new[175]|giv[177]|new[180]	_	_
19-24	2982-2983	,	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-25	2984-2993	migration	abstract[174]|abstract[175]|abstract[177]|abstract	new[174]|new[175]|giv[177]|new	_	_
19-26	2994-2995	,	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-27	2996-2999	and	abstract[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
19-28	3000-3006	escape	abstract[174]|abstract[175]|abstract[177]|abstract[182]	new[174]|new[175]|giv[177]|new[182]	_	_
19-29	3007-3011	from	abstract[174]|abstract[175]|abstract[177]|abstract[182]	new[174]|new[175]|giv[177]|new[182]	_	_
19-30	3012-3015	the	abstract[174]|abstract[175]|abstract[177]|abstract[182]|abstract[183]	new[174]|new[175]|giv[177]|new[182]|new[183]	_	_
19-31	3016-3022	immune	abstract[174]|abstract[175]|abstract[177]|abstract[182]|abstract[183]	new[174]|new[175]|giv[177]|new[182]|new[183]	_	_
19-32	3023-3029	system	abstract[174]|abstract[175]|abstract[177]|abstract[182]|abstract[183]	new[174]|new[175]|giv[177]|new[182]|new[183]	_	_
19-33	3030-3031	.	_	_	_	_

#Text=However , the correlation between EMT and GSCs in glioblastoma has not been reported to date .
20-1	3032-3039	However	_	_	_	_
20-2	3040-3041	,	_	_	_	_
20-3	3042-3045	the	abstract[184]	new[184]	_	_
20-4	3046-3057	correlation	abstract[184]	new[184]	_	_
20-5	3058-3065	between	abstract[184]	new[184]	_	_
20-6	3066-3069	EMT	abstract[184]|abstract	new[184]|giv	coref	21-8
20-7	3070-3073	and	abstract[184]	new[184]	_	_
20-8	3074-3078	GSCs	abstract[184]|abstract	new[184]|giv	coref	21-10
20-9	3079-3081	in	abstract[184]	new[184]	_	_
20-10	3082-3094	glioblastoma	abstract[184]|abstract	new[184]|giv	coref	21-24
20-11	3095-3098	has	_	_	_	_
20-12	3099-3102	not	_	_	_	_
20-13	3103-3107	been	_	_	_	_
20-14	3108-3116	reported	_	_	_	_
20-15	3117-3119	to	_	_	_	_
20-16	3120-3124	date	time	new	_	_
20-17	3125-3126	.	_	_	_	_

#Text=In this study , we focused on EMT and GSCs and performed multivariable analyses using the expression data and OS in patients with glioblastoma .
21-1	3127-3129	In	_	_	_	_
21-2	3130-3134	this	abstract[189]	new[189]	_	_
21-3	3135-3140	study	abstract[189]	new[189]	_	_
21-4	3141-3142	,	_	_	_	_
21-5	3143-3145	we	person	acc	ana	22-11
21-6	3146-3153	focused	_	_	_	_
21-7	3154-3156	on	_	_	_	_
21-8	3157-3160	EMT	abstract	giv	_	_
21-9	3161-3164	and	_	_	_	_
21-10	3165-3169	GSCs	abstract	giv	_	_
21-11	3170-3173	and	_	_	_	_
21-12	3174-3183	performed	_	_	_	_
21-13	3184-3197	multivariable	abstract[193]	new[193]	_	_
21-14	3198-3206	analyses	abstract[193]	new[193]	_	_
21-15	3207-3212	using	abstract[193]	new[193]	_	_
21-16	3213-3216	the	abstract[193]|abstract[195]	new[193]|new[195]	_	_
21-17	3217-3227	expression	abstract[193]|abstract|abstract[195]	new[193]|giv|new[195]	_	_
21-18	3228-3232	data	abstract[193]|abstract[195]	new[193]|new[195]	_	_
21-19	3233-3236	and	abstract[193]	new[193]	_	_
21-20	3237-3239	OS	abstract[193]|abstract[196]	new[193]|giv[196]	_	_
21-21	3240-3242	in	abstract[193]|abstract[196]	new[193]|giv[196]	_	_
21-22	3243-3251	patients	abstract[193]|abstract[196]|person[197]	new[193]|giv[196]|giv[197]	coref	22-8[202_197]
21-23	3252-3256	with	abstract[193]|abstract[196]|person[197]	new[193]|giv[196]|giv[197]	_	_
21-24	3257-3269	glioblastoma	abstract[193]|abstract[196]|person[197]|abstract	new[193]|giv[196]|giv[197]|giv	coref	22-8
21-25	3270-3271	.	_	_	_	_

#Text=To determine the distribution of survival of glioblastoma patients , we composed prognosis prediction formulae for the following components :
22-1	3272-3274	To	_	_	_	_
22-2	3275-3284	determine	_	_	_	_
22-3	3285-3288	the	abstract[199]	new[199]	_	_
22-4	3289-3301	distribution	abstract[199]	new[199]	_	_
22-5	3302-3304	of	abstract[199]	new[199]	_	_
22-6	3305-3313	survival	abstract[199]|event	new[199]|giv	_	_
22-7	3314-3316	of	abstract[199]	new[199]	_	_
22-8	3317-3329	glioblastoma	abstract[199]|abstract|person[202]	new[199]|giv|giv[202]	coref	24-10
22-9	3330-3338	patients	abstract[199]|person[202]	new[199]|giv[202]	_	_
22-10	3339-3340	,	_	_	_	_
22-11	3341-3343	we	person	giv	_	_
22-12	3344-3352	composed	_	_	_	_
22-13	3353-3362	prognosis	abstract|event[205]|abstract[206]	giv|giv[205]|new[206]	_	_
22-14	3363-3373	prediction	event[205]|abstract[206]	giv[205]|new[206]	_	_
22-15	3374-3382	formulae	abstract[206]	new[206]	_	_
22-16	3383-3386	for	abstract[206]	new[206]	_	_
22-17	3387-3390	the	abstract[206]|abstract[207]	new[206]|new[207]	_	_
22-18	3391-3400	following	abstract[206]|abstract[207]	new[206]|new[207]	_	_
22-19	3401-3411	components	abstract[206]|abstract[207]	new[206]|new[207]	_	_
22-20	3412-3413	:	_	_	_	_

#Text=epithelium ( EPI ) , mesenchyme ( MES ) , glioma ( GLI ) , GSC , molecular target therapy ( MTT ) genes , and potential glioma biomarkers ( PGBs ) .
23-1	3414-3424	epithelium	substance	new	_	_
23-2	3425-3426	(	_	_	_	_
23-3	3427-3430	EPI	abstract	new	_	_
23-4	3431-3432	)	_	_	_	_
23-5	3433-3434	,	_	_	_	_
23-6	3435-3445	mesenchyme	abstract	new	appos	23-8
23-7	3446-3447	(	_	_	_	_
23-8	3448-3451	MES	abstract	giv	_	_
23-9	3452-3453	)	_	_	_	_
23-10	3454-3455	,	_	_	_	_
23-11	3456-3462	glioma	abstract	giv	appos	23-13
23-12	3463-3464	(	_	_	_	_
23-13	3465-3468	GLI	abstract	giv	coref	23-28
23-14	3469-3470	)	_	_	_	_
23-15	3471-3472	,	_	_	_	_
23-16	3473-3476	GSC	abstract	giv	_	_
23-17	3477-3478	,	_	_	_	_
23-18	3479-3488	molecular	abstract[216]|abstract[218]	new[216]|new[218]	appos|coref	23-22[0_216]|24-3[222_218]
23-19	3489-3495	target	abstract|abstract[216]|abstract[218]	new|new[216]|new[218]	_	_
23-20	3496-3503	therapy	abstract[216]|abstract[218]	new[216]|new[218]	_	_
23-21	3504-3505	(	abstract[218]	new[218]	_	_
23-22	3506-3509	MTT	abstract|abstract[218]	giv|new[218]	_	_
23-23	3510-3511	)	abstract[218]	new[218]	_	_
23-24	3512-3517	genes	abstract[218]	new[218]	_	_
23-25	3518-3519	,	_	_	_	_
23-26	3520-3523	and	_	_	_	_
23-27	3524-3533	potential	abstract[220]	new[220]	appos	23-31[0_220]
23-28	3534-3540	glioma	abstract|abstract[220]	giv|new[220]	_	_
23-29	3541-3551	biomarkers	abstract[220]	new[220]	_	_
23-30	3552-3553	(	_	_	_	_
23-31	3554-3558	PGBs	abstract	giv	_	_
23-32	3559-3560	)	_	_	_	_
23-33	3561-3562	.	_	_	_	_

#Text=Consequently , several candidate genes were identified as promising glioblastoma predictors .
24-1	3563-3575	Consequently	_	_	_	_
24-2	3576-3577	,	_	_	_	_
24-3	3578-3585	several	abstract[222]	giv[222]	_	_
24-4	3586-3595	candidate	abstract[222]	giv[222]	_	_
24-5	3596-3601	genes	abstract[222]	giv[222]	_	_
24-6	3602-3606	were	_	_	_	_
24-7	3607-3617	identified	_	_	_	_
24-8	3618-3620	as	_	_	_	_
24-9	3621-3630	promising	abstract[224]	new[224]	_	_
24-10	3631-3643	glioblastoma	abstract|abstract[224]	giv|new[224]	_	_
24-11	3644-3654	predictors	abstract[224]	new[224]	_	_
24-12	3655-3656	.	_	_	_	_
